Clene Showcases CNM-Au8® Advancements at Neurology Session

Clene ( (CLNN) ) just unveiled an update.

On April 8, 2025, Clene announced the presentation of evidence demonstrating remyelination and neuronal repair with their CNM-Au8® treatment during the VISIONARY-MS LTE at the American Academy of Neurology Late-Breaking Science Session. This announcement highlights Clene’s ongoing efforts in advancing neurological treatments, potentially strengthening its position in the medical research industry and offering promising implications for stakeholders involved in neurological disorder therapies.

Spark’s Take on CLNN Stock

According to Spark, TipRanks’ AI Analyst, CLNN is a Underperform.

Clene’s overall stock score reflects its precarious financial condition, underscored by declining revenues and persistent losses. Technical analysis signals a bearish trend, and the company’s negative valuation metrics further weaken investor confidence. Without any positive guidance from earnings calls or corporate events, the stock remains high-risk.

To see Spark’s full report on CLNN stock, click here.

More about Clene

YTD Price Performance: -50.65%

Average Trading Volume: 49,084

Technical Sentiment Signal: Strong Buy

Current Market Cap: $23.22M

For an in-depth examination of CLNN stock, go to TipRanks’ Stock Analysis page.